登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Lancet，5月28日，Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-05-29

  • Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort

    Pilar Vizcarra, MD

    María J Pérez-Elías, PhD

    Carmen Quereda, PhD

    Ana Moreno, PhD

    María J Vivancos, PhD

    Fernando Dronda, PhD

    et al.

    Published:May 28, 2020DOI:https://doi.org/10.1016/S2352-3018(20)30164-8

    Summary

    Background

    Information about incidence, clinical characteristics, and outcomes of HIV-infected individuals with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is scarce. We characterised individuals with COVID-19 among a cohort of HIV-infected adults in Madrid.

    Methods

    In this observational prospective study, we included all consecutive HIV-infected individuals (aged ≥18 years) who had suspected or confirmed COVID-19 as of April 30, 2020, at the Hospital Universitario Ramón y Cajal (Madrid, Spain). We compared the characteristics of HIV-infected individuals with COVID-19 with a sample of HIV-infected individuals assessed before the COVID-19 pandemic, and described the outcomes of individuals with COVID-19.

  • 原文来源：https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30164-8/fulltext
28浏览量
原文链接
相关报告

  • 《5月28日_COVID-19对HIV感染者的临床影响》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-29
    • 信息名称：COVID-19对HIV感染者的临床影响 1.时间：2020年5月28日 2.机构或团队：拉蒙和卡哈尔大学医院 3.事件概要： 拉蒙和卡哈尔大学医院在THE LANCET发表论文“Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort”。 目前关于感染严重急性呼吸道综合征（SARS-CoV-2）的HIV感染者的发病率、临床特征和结局的信息很少。文章对马德里一组艾滋病毒感染成年人中的COVID-19患者的临床特征进行描述。文章纳入了2020年4月30日前在西班牙马德里拉蒙和卡哈尔大学医院怀疑或确诊COVID-19的所有艾滋病毒感染者（年龄≥18岁）。文章将HIV感染者的COVID-19特征与COVID-19大流行之前评估的HIV感染者样本进行了比较，并描述了COVID-19患者的结局。研究结果显示，51例HIV感染者诊断为COVID-19（发病率1.8%）。患者平均年龄53.3岁（SD 9.5）；女性占8人（16%），男性占43人（84%）。35例（69%）合并感染病例经实验室确诊为COVID-19，28例（55%）需要住院治疗。51例确诊为COVID-19患者的年龄和CD4细胞计数与1288例未诊断为COVID-19的HIV感染者相似；然而，患有COVID-19的32人（63%）至少有一种合并症（主要是高血压和糖尿病），而没有COVID-19的495人（38%）至少有一种合并症（p=0.00059）。COVID-19在HIV感染者中的临床、分析和放射学表现与普通人群相似。6（12%）人病危，2人CD4计数少于200 cells/μL，2人（4%）死亡。文章认为，艾滋病毒感染者不应视为免疫SARS-CoV-2感染或患严重疾病的风险较低，他们应该接受与一般人群相同的治疗方法。 4.附件： 原文链接：https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30164-8/fulltext
    139浏览量
    原文链接

  • 《Lancet，6月16日，GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-18
    • GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study Giacomo De Luca, MD Giulio Cavalli, MD Corrado Campochiaro, MD Emanuel Della-Torre, MD Piera Angelillo, MD Alessandro Tomelleri, MD et al. Show all authors Published:June 16, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30170-3 Summary Background Mortality in patients with COVID-19 pneumonia and systemic hyperinflammation is high. We aimed to examine whether mavrilimumab, an anti-granulocyte–macrophage colony-stimulating factor receptor-α monoclonal antibody, added to standard management, improves clinical outcomes in patients with COVID-19 pneumonia and systemic hyperinflammation. Methods This single-centre prospective cohort study included patients aged 18 years or older who were admitted to San Raffaele Hospital (Milan, Italy) with severe COVID-19 pneumonia, hypoxia, and systemic hyperinflammation. Patients received a single intravenous dose (6 mg/kg) of mavrilimumab added to standard care given by the hospital at the time. The control group consisted of contemporaneous patients with similar baseline characteristics who received standard care at the same hospital. The main outcome was time to clinical improvement (defined as improvement of two or more points on the seven-point ordinal scale of clinical status). Other outcomes included proportion of patients achieving clinical improvement, survival, mechanical ventilation-free survival, and time to fever resolution. Adverse events were monitored daily.
    79浏览量
    原文链接